miR-1207-3p Is a Novel Prognostic Biomarker of Prostate Cancer

Abstract

MicroRNAs (miRNAs) have been found to be dysregulated in prostate cancer (PCa). In this study, we investigated if miR-1207-3p is capable of distinguishing between indolent and aggressive PCa and if it contributes to explaining the disproportionate aggressiveness of PCa in men of African ancestry (moAA). A total of 404 patients with primary adenocarcinoma of the prostate were recruited between 1988 and 2003 at the Moffitt Cancer Center, Tampa, FL, USA. Patient clinicopathological features and demographic characteristics such as race were identified. RNA samples from 404 postprostatectomy prostate tumor tissue samples were analyzed by real-time quantitative reverse transcription polymerase chain reaction for the mRNA expression of miR-1207-3p. miR-1207-3p expression in PCa that resulted in overall death or PCa-specific death is significantly higher than in PCa cases that did not. The same positive correlation holds true for other clinical characteristics such as biochemical recurrence, Gleason score, clinical stage, and prostate-specific antigen level. Furthermore, miR-1207-3p expression was significantly less in moAA in comparison to Caucasian men. We also evaluated whether miR-1207-3p is associated with clinical outcomes adjusted for age at diagnosis and tumor stage in the modeling. Using competing risk regression, the PCa patients with a high miR-1207-3p expression (≥ 6 vs 3) had a high risk to develop PCa recurrence (hazard rate = 2.5, P < .001) adjusting for age at diagnosis and tumor stage. In conclusion, miR-1207-3p is a promising novel prognostic biomarker for PCa. Furthermore, miR-1207-3p may also be important in explaining the disproportionate aggressiveness of PCa in moAA.

Interactions ofPVT1andCASC11on Prostate Cancer Risk in African Americans

“…Males of African ancestry have a significantly lower expression of miR-1207-3p in prostate cancer tissues compared with those of Caucasian men. The difference in expression could play a great role in explaining the reason why prostate cancer is more aggressive in AA men (56). Das and Ogunwobi suggest that miR-1207 underexpression may be associated with the onset of progression of prostate cancer and correlates with tumor aggressiveness (57).…”

A novel microRNA-1207-3p/FNDC1/FN1/AR regulatory pathway in prostate cancer

“…Prostate cancer (PCa) is the most commonly diagnosed male cancer in the western world [1,2] . With an estimated 22,800 newly diagnosed men in the US in 2015, PCa is a major cause of cancer morbidity and mortality [3] .…”

“…With an estimated 22,800 newly diagnosed men in the US in 2015, PCa is a major cause of cancer morbidity and mortality [3] . Although there has been progress made in the field, several areas of critical unmet needs remain in PCa, such as the molecular mechanisms underlying its development and progression [1,2,[4][5][6] . The complexity of the disease lies in its heterogeneity [1,2,7] .…”

“…Although there has been progress made in the field, several areas of critical unmet needs remain in PCa, such as the molecular mechanisms underlying its development and progression [1,2,[4][5][6] . The complexity of the disease lies in its heterogeneity [1,2,7] . The current tool for screening for PCa, prostate specific antigen (PSA), is highly controversial as it is not PCa-specific and has a high false positive rate [8,9] .…”

“…It is now well known that the 8q24 human chromosomal locus has profound genomic instability in PCa [2,[21][22][23][24] . Several studies, including one published recently from our lab, "PVT1 exon 9: a potential biomarker of aggressive prostate cancer?"…”